Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP

Krystal Biotech, Inc. KRYS

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$389.1M
▲ 33.9% YoY
$204.8M
▲ 129.7% YoY
$188.9M
▲ 58.5% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Krystal Biotech, Inc. is a commercial-stage biotechnology company that discovers, develops, manufactures and commercializes genetic medicines to treat diseases with high unmet medical needs. Its first commercial product, VYJUVEK, is approved in the United States, the European Union, and Japan for the treatment of dystrophic epidermolysis bullosa, and the company launched VYJUVEK in the United States in 2023 and started launching it in Europe and Japan in 2025. The company's technology platform is supported by two in-house, commercial-scale Current Good Manufacturing Practice manufacturing facilities. As of February 11, 2026, the company had 295 full-time employees. Its principal offices are located at 2100 Wharton Street, Suite 701, Pittsburgh, PA 15203. In April 2019, the company incorporated Jeune Aesthetics, Inc., a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. The company commenced operations in April 2016 and converted from a California limited liability company to a Delaware C-corporation in March 2017, changing its name from Krystal Biotech LLC to Krystal Biotech, Inc.

Written from the business description in Krystal Biotech, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 17 February 2026. Every sentence was checked against that document before publication.

Growth

USD 389.1M
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 389.1 · Net income 204.8
150M300M-50M-100M
2016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

53 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 41.5% · Net 52.6%
20%40%-100%-200%
201620202025
ROE
FY2025 · ROE 18.9%
-100%-200%-300%
201620202025
Three returns, three denominators.

Each USD of equity produced 19 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 188.9
100M200M-100M-200M
201620202025

Total assetsUSD 1.3B
EquityUSD 1.2B
CashUSD 496.3M
Current ratio9.95×

Equity funds 91% of total assets.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
KRYS, 10-year financial record
Metric 2025202420232022202120202019201820172016
Revenue $B0.40.30.10.00.0◌◌◌◌◌
Operating income $B0.20.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
EBITDA $B0.20.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
Income tax $B−0.00.00.00.00.00.00.00.00.0◌
Net income $B0.20.10.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0
Free cash flow $B0.20.1−0.1−0.2−0.1−0.0−0.0−0.0−0.0−0.0
EPS, diluted $6.843.000.39−5.49−3.13−1.71−1.20−0.97−1.48−1.31
Dividend / sh $◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————
ROE %18.910.31.7−25.1−15.7−13.0−12.1−13.4−31.8−397.9
Shares out B0.030.030.030.030.030.020.020.010.010.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 40 reconciliationsAUDITED

Reconciled in 10 of the 10 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. Nine checks were skipped: EPS is not tagged before 2016.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2016

Share this section

Download image